
ICML 2025 | What do the initial results from the LOTIS-7 trial suggest for loncastuximab tesirine plus glofitamab in R/R DLBCL?
During the 18th International Conference on Malignant Lymphoma (ICML), Jun 17–21, 2025, Lugano, CH, the Lymphoma Hub was pleased to speak with Juan Pablo Alderuccio, University of Miami, Florida, US. We asked, What do the initial results from the LOTIS-7 (NCT04970901) trial suggest for loncastuximab tesirine plus glofitamab in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)?
In this interview, Dr Alderuccio discussed preliminary data presented at the 18-ICML from the LOTIS-7 clinical trial, a multicenter study exploring novel combination therapies in relapsed or refractory…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.